Furukawa Taku, Lankadeva Yugeesh, Baldwin Ian, Ow Pei Chen Connie, Hood Sally, Schneider Antoine, Decosterd Laurent A, May Clive N, Bellomo Rinaldo
Preclinical Critical Care Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia,
Preclinical Critical Care Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
Blood Purif. 2025;54(2):102-110. doi: 10.1159/000542332. Epub 2024 Nov 1.
Hemoadsorption can be used as adjunctive therapy for sepsis. However, there is limited evidence regarding its antibiotic removal. In this in vivo preclinical study, we aimed to evaluate the removal of meropenem and piperacillin with the HA380 hemoadsorption cartridge.
Healthy adult sheep (n = 6) received 2 g of meropenem and 4 g of piperacillin intravenously for 30 min followed by hemoadsorption with a HA380 cartridge at a blood flow rate of 120 mL/min for 4 h. The sorbent-based removal ratio, clearance, and mass removal were calculated at multiple time points.
The sorbent-based removal ratio of meropenem decreased from 95.4% (SD 1.8) at 10 min to less than 20% at 4 h of hemoadsorption. Its cumulative sorbent-based mass removal was 386.6 mg (SD 78.8) over 4 h with 65.6% (SD 7.1) occurring in the first 60 min. In contrast, the sorbent-based removal ratio of piperacillin decreased more gradually from 98.4% (SD 0.6) at 10 min to 37.4% (SD 7.2) at 4 h. Its cumulative sorbent-based mass removal was 647.4 mg (SD 191.3) over 4 h with 63.4% (SD 4.2) occurring in the first 60 min. The overall sorbent-based clearance of piperacillin was significantly greater than meropenem (pgroup < 0.0001).
Hemoadsorption with the HA380 cartridge removed meropenem and piperacillin throughout a 4-h period, with high clearances at the start. Our findings can be used to inform dosing decisions during hemoadsorption in septic patients, there may be the need to consider increasing the doses of these antibiotics by 15-25% to prevent underdosing.
血液吸附可作为脓毒症的辅助治疗方法。然而,关于其抗生素清除作用的证据有限。在这项体内临床前研究中,我们旨在评估HA380血液吸附柱对美罗培南和哌拉西林的清除效果。
健康成年绵羊(n = 6)静脉注射2 g美罗培南和4 g哌拉西林,持续30分钟,随后使用HA380柱以120 mL/分钟的血流速度进行4小时的血液吸附。在多个时间点计算基于吸附剂的清除率、清除量和质量清除量。
美罗培南基于吸附剂的清除率在血液吸附10分钟时为95.4%(标准差1.8),在4小时时降至20%以下。4小时内其基于吸附剂的累积质量清除量为386.6 mg(标准差78.8),其中65.6%(标准差7.1)发生在前60分钟。相比之下,哌拉西林基于吸附剂的清除率从10分钟时的98.4%(标准差0.6)更缓慢地降至4小时时的37.4%(标准差7.2)。4小时内其基于吸附剂的累积质量清除量为647.4 mg(标准差191.3),其中63.